ReviewImmunological reviews2011
Smallpox vaccines: targets of protective immunity.
Review in Immunological reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Osteomyelitis variolosa, an issue inherited from the past: case report and systematic review.Orphanet journal of rare diseases · 2021Pooled it
- A n-heneicosane solid emulsion as a single-dose subunit vaccine elicits broad and durable immune responses in an aged and a Pox virus model.International journal of pharmaceutics: X · 2026Article
- Structure prediction and drug screening targeting monkeypox virus polymerase and surface proteins.Journal of computer-aided molecular design · 2026Article
- Enhanced replication and immunogenicity of a genome-modified non-replicating vaccinia virus Tiantan strain for robust low-dose protection in mice.Journal of virology · 2026Article
- Tandem triplicate A29L peptide elicits robust immune responses against monkeypox virus in mice.Applied microbiology and biotechnology · 2026Article
- B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.Nature communications · 2026Article
- Advanced strategies for the diagnosis, treatment, and vaccination of monkeypox.Journal of nanobiotechnology · 2026Review
- Robust Adaptive Immunity to MPXV in Older People Who Received Childhood Vaccinia Vaccination.Biology · 2026Article
- Machine learning-supported framework for the classification of mpox infection and MVA immunization from multiplexed serology data.Nature communications · 2025Article
- Immunoinformatic based designing of highly immunogenic multi-epitope subunit vaccines to stimulate an adaptive immune response against Junin virus.Molecular diversity · 2025Article
- Article
- Article
- Anti-M1R/B6R antibody characterization and bispecific design for enhanced orthopoxvirus protection.EMBO molecular medicine · 2025Article
- Multivalent mpox protein nanoparticle vaccines confer cross-protection against orthopoxvirus infection.PLoS pathogens · 2025Article
- Vaccinia and Monkeypox Virus-Neutralizing Antibodies in People Living with HIV: A Serological Study in a Orthopoxvirus-Endemic, Low-Income Region in Brazil.Pathogens (Basel, Switzerland) · 2025Article
- Bivalent single-domain antibodies show potent mpox virus neutralization through M1R antigen.Communications biology · 2025Article
- Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox.NPJ vaccines · 2025Article
- Poxvirus structural biology for application to vaccine design.Trends in immunology · 2025Review
- Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates.Nature communications · 2025Article
- Generation and characterization of neutralizing antibodies against M1R and B6R proteins of monkeypox virus.Nature communications · 2025Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The eradication of smallpox, one of the great triumphs of medicine, was accomplished through the prophylactic administration of live vaccinia virus, a comparatively benign relative of variola virus, the causative agent of smallpox. Nevertheless, recent fears that variola virus may be used as a biological weapon together with the present susceptibility of unimmunized populations have spurred the development of new-generation vaccines that are safer than the original and can be produced by modern methods. Predicting the efficacy of such vaccines in the absence of human smallpox, however, depends on understanding the correlates of protection. This review outlines the biology of poxviruses with particular relevance to vaccine development, describes protein targets of humoral and cellular immunity, compares animal models of orthopoxvirus disease with human smallpox, and considers the status of second- and third-generation smallpox vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.